Home/Products /lenalidomide-10-mg-capsule

LENABOT 10 Capsule: Lenalidomide 10 mg - Immunomodulatory Therapy

Name: LENABOT 10: Lenalidomide 10 mg Capsule
Brand: Lenabot Capsule
Rating: 4.8 (150 reviews)

Mechanism of Action: How Lenalidomide Modifies the Cancer Microenvironment

Primary Indication: Multiple Myeloma (MM) - Induction, Consolidation, and Maintenance

Key Application: Myelodysplastic Syndromes (MDS) with Chromosome 5q Deletion

Important Safety and Monitoring Protocols (REMS/Risk Management)

Secure Your Monopoly: LENABOT 10 PCD Pharma Franchise for Hematological Oncology

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Lenalidomide 10 mg capsule strip for multiple myeloma

Oral therapy capsule for Myelodysplastic Syndromes (MDS)

Oncology PCD Pharma franchise marketing visual for Lenalidomide

Lenabot 10 mg (Lenalidomide) Safety and Patient Information Leaflet PDF

Lenabot Capsule

Composition : Lenalidomide 10 mg Capsule

Dosage Form : Capsule

Packaging Type : in a Bottle

Packaging : 30 Capsules

Price : ₹0/-

Please Contact For Best Price

LENABOT 10 Capsules (Lenalidomide 10 mg) is a cornerstone oral medication in hematological oncology, classified as an Immunomodulatory Drug (IMiD). It is primarily used for the management of Multiple Myeloma (MM), a complex, chronic blood cancer.

Mechanism and Impact:Lenalidomide has a three-pronged effect:

Immunomodulation: It enhances the body's natural killer (NK) and T-cell anti-tumor responses.
Anti-Angiogenesis: It prevents the formation of new blood vessels needed by the tumor.
Direct Anti-Proliferation: It inhibits the growth and survival of myeloma cells.This powerful combination makes it essential for achieving deep, durable responses in MM patients, often in combination with Dexamethasone.

Key Therapeutic Uses:

Multiple Myeloma: Used in newly diagnosed and relapsed/refractory patients, as well as for long-term maintenance therapy.
Myelodysplastic Syndromes (MDS): Specifically for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion $5 q$ cytogenetic abnormality.

Due to the chronic nature of MM and the critical safety protocols required for dispensing (e.g., REMS programs), Lenalidomide 10 mg represents a high-barrier, high-trust, and remarkably stable market segment. We offer an exclusive PCD Pharma Franchise opportunity for LENABOT 10, securing a dominant position in the high-value hematological oncology sector.

About the Product

Mechanism and Impact:Lenalidomide has a three-pronged effect:

Immunomodulation: It enhances the body's natural killer (NK) and T-cell anti-tumor responses.
Anti-Angiogenesis: It prevents the formation of new blood vessels needed by the tumor.
Direct Anti-Proliferation: It inhibits the growth and survival of myeloma cells.This powerful combination makes it essential for achieving deep, durable responses in MM patients, often in combination with Dexamethasone.

Key Therapeutic Uses:

Multiple Myeloma: Used in newly diagnosed and relapsed/refractory patients, as well as for long-term maintenance therapy.
Myelodysplastic Syndromes (MDS): Specifically for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion $5 q$ cytogenetic abnormality.

Common side effects include nausea, dizziness, stomach discomfort, muscle pain, headache, and an increased risk of bleeding or bruising.

Rosutyle Gold 20/150 Tablet is prescribed for individuals at high risk of cardiovascular diseases, including heart attack, stroke, and atherosclerosis, especially those with high cholesterol and hypertension.

Use only under medical supervision. Regular monitoring of cholesterol levels, liver function, and bleeding risk is recommended.

Store at room temperature (15-30°C) in a dry place away from direct sunlight and moisture. Keep out of reach of children.